改善冠脉微循环障碍对减少心血管事件的发生具有重要的临床意义。内皮-血小板-炎症网络调控异常导致的冠状动脉微血管栓塞是冠脉微循环障碍的一个重要发病机制。有证据显示，microRNA（miRNA）参与调节血管内皮功能异常、血小板活化及炎症相关的多种重要蛋白表达，对冠脉微循环的结构和功能有着重要调控作用。以往研究表明，川芎嗪有保护血管内皮、抗血小板和抗炎的作用，但其干预冠脉微循环障碍的效应和分子机理尚不明确。本课题在前期研究工作的基础上，应用冠脉微血栓动物模型模拟冠脉微循环障碍，以冠脉微循环障碍状态下差异表达的miRNA为研究切入点，探索在内皮-血小板-炎症网络中起关键调控作用的目标miRNA-靶基因通路，证实活血化瘀中药成分川芎嗪对冠脉微循环障碍的干预效应，并从目标miRNA-靶基因通路阐明其分子机理，为川芎嗪防治冠心病的临床转化应用提供实验依据。

Improving coronary microvascular dysfunction (CMD) is of great clinical significance for reducing cardiovascular events. The coronary microvascular thrombosis caused by endothelium-platelet-inflammation network disorder is an important pathogenesis of CMD. Numerous studies have shown that microRNA (miRNA) play important roles in the structure and function of coronary microcirculation via regulating the expression of protein involved in vascular endothelial dysfunction, platelet activation and inflammation. According to literatures, ligustrazine could improve endothelial function and exert antiplatelet and anti-inflammatory effects. However, the regulatory effect and mechanism of ligustrazine on CMD remain unclear. Based on our previous research, we establish coronary microthrombus animal model to simulate the occurrence of CMD and decteted the differently expressed miRNAs, then verify the regulatory effect of ligustrazine on CMD and explore the molecular mechanism through the key miRNA-gene pathways involved in endothelium-platelet-inflammation network. The present study may provide experimental evidence and molecular targeting for clinical application of ligustrazine in prevention and treatment of coronary heart disease.